近距离内射合集

The Heart Hospital of New Mexico at Lovelace Medical Center has joined a potentially groundbreaking clinical trial addressing heart failure.

The CORCINCH-HF study, which the Lovelace Health System hospital is the first in the state to join, is tracking the safety and efficacy of California-based Ancora Heart鈥檚 AccuCinch ventricular restoration system. The device aims to improve the structure and function of the muscular organ and increase life expectancy. Lovelace medical staff surgically inserted the device into the first New Mexico patient on Tuesday.

Dr. Mark Bieniarz, an interventional cardiologist with the New Mexico Heart Institute and Lovelace Medical Group and the trial鈥檚 principal investigator, told the Journal the procedure lasted four hours.

鈥淚t was perfect,鈥� he said.

The device is placed into a patient鈥檚 heart, with anchors underneath the mitral valve and spacers that cinch one part of the organ to improve the function in other areas, Bieniarz said.

鈥淲hat we鈥檝e seen in the pilot trial 鈥� is the rest of the heart starts responding,鈥� Bieniarz said. 鈥淧eople鈥檚 hearts not only shrink down 鈥� their symptoms improve.鈥�

Bieniarz said the trial looks to enroll some 450 patients, noting that about half of those slots have been filled. So far, 100 devices have been surgically inserted into patients across the globe. Lovelace has looked at three additional New Mexico patients who could be a good fit for the trial.

鈥淭he trial can only be done with people whose heart muscle is a certain thickness,鈥� Bieniarz said. With the other prospects, 鈥渨e are waiting on CAT scans to assess the size of the heart muscle.鈥�

Lovelace has a long history of clinical trials associated with the heart, ranging from drug to device trials, Bieniarz said. That includes the STEMI-DTU trial, which placed a pump in the heart to treat people experiencing heart attacks.

鈥淲e were the second-highest enroller in the 近距离内射合集 States, third-highest enroller in the world,鈥� he said. 鈥淚t was a remarkable trial.鈥�

But drug trials in recent years have become more common for treating heart failure in particular, Bieniarz said. That鈥檚 part of what made joining the CORCINCH-HF study appealing.

鈥淧eople are facing a really hard decision when they are in end-stage heart failure 鈥� whether they鈥檙e going to have one of these advanced therapies like 鈥� a heart transplant or just going toward supportive care,鈥� Bieniarz said. 鈥淭his is going to fit a niche between having to make that hard decision and say, 鈥楬ey, there鈥檚 an involved device that may very well help me.鈥欌��